問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Chang Bing Show Chwan Memorial Hospital

  • 0

    Total Beds

  • 0

    Total Doctors

  • pidb_editor
  • 505Changhua CountyChanghua Lugang

Recruiting Trial

12Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

15Cases

2023-05-10 - 2025-04-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2024-06-01 - 2027-07-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2024-10-01 - 2035-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting3Sites

2025-06-01 - 2027-09-30

Phase III

Active
A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator's Choice in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent BTK Inhibitors

  • Condition/Disease

    Chronic Lymphocytic Leukemia 、Small Lymphocytic Lymphoma

  • Test Drug

    錠劑

Participate Sites
5Sites

Recruiting5Sites

2019-01-01 - 2023-09-30

Phase I

Completed
A Phase 1/2, open-label, multi-center study of the safety and efficacy of KY1044 as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies

  • Condition/Disease

    Advanced/metastatic malignancies, and preferred indications: head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC),hepatocellular carcinoma (HCC), esophageal cancer, gastric cancer, melanoma,renal cell cancer, pancreatic cancer, cervical cancer, and triple negative breastcancer (BC)

  • Test Drug

    KY1044

Participate Sites
7Sites

Not yet recruiting4Sites

Recruiting2Sites

Terminated1Sites

2021-09-02 - 2026-09-09

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-04-30 - 2028-09-30

Phase III

Active
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)

  • Condition/Disease

    Chronic Lymphocytic Leukemia

  • Test Drug

    錠劑

Participate Sites
5Sites

Recruiting5Sites

2025-03-01 - 2029-12-31

Others

Active
A Double-Blind, Randomized, Active-Controlled, Parallel-group, Phase 1/3 Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma

  • Condition/Disease

    Refractory or Relapsed Multiple Myeloma

  • Test Drug

    皮下注射劑

Participate Sites
6Sites

Recruiting6Sites

2024-02-28 - 2030-03-31

Phase III

Active
A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-COP to the CHOP Regimen Alone in Newly Diagnosed Patients with Peripheral T-Cell Lymphoma

  • Condition/Disease

    Peripheral T-Cell Lymphoma

  • Test Drug

    injection

Participate Sites
6Sites

Recruiting6Sites

2024-12-26 - 2028-10-20

Phase III

Active
A Phase 3, Open-Label, Randomized, Multinational Study to Investigate the Anti-tumor Efficacy of Golidocitinib versus Investigator’s Choice in Adult Patients with Relapsed/Refractory Peripheral T-cell Lymphoma

  • Condition/Disease

    Relapsed/Refractory Peripheral T-cell Lymphoma

  • Test Drug

    injective

Participate Sites
8Sites

Recruiting8Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB